Home > Publications Database > Toward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings. > print

001     164058
005     20230915090546.0
024 7 _ |a 10.1038/s41531-022-00301-2
|2 doi
024 7 _ |a pmid:35440571
|2 pmid
024 7 _ |a pmc:PMC9018912
|2 pmc
024 7 _ |a altmetric:126937397
|2 altmetric
037 _ _ |a DZNE-2022-00721
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Feldmann, Lucia K
|0 0000-0003-1290-208X
|b 0
245 _ _ |a Toward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings.
260 _ _ |a London [u.a.]
|c 2022
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655118377_6957
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Adaptive deep brain stimulation (aDBS) is a promising concept for feedback-based neurostimulation, with the potential of clinical implementation with the sensing-enabled Percept neurostimulator. We aim to characterize chronic electrophysiological activity during stimulation and to validate beta-band activity as a biomarker for bradykinesia. Subthalamic activity was recorded during stepwise stimulation amplitude increase OFF medication in 10 Parkinson's patients during rest and finger tapping. Offline analysis of wavelet-transformed beta-band activity and assessment of inter-variable relationships in linear mixed effects models were implemented. There was a stepwise suppression of low-beta activity with increasing stimulation intensity (p = 0.002). Low-beta power was negatively correlated with movement speed and predictive for velocity improvements (p < 0.001), stimulation amplitude for beta suppression (p < 0.001). Here, we characterize beta-band modulation as a chronic biomarker for motor performance. Our investigations support the use of electrophysiology in therapy optimization, providing evidence for the use of biomarker analysis for clinical aDBS.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Lofredi, Roxanne
|b 1
700 1 _ |a Neumann, Wolf-Julian
|0 0000-0002-6758-9708
|b 2
700 1 _ |a Al-Fatly, Bassam
|0 0000-0003-0067-6177
|b 3
700 1 _ |a Roediger, Jan
|0 0000-0003-2814-3532
|b 4
700 1 _ |a Bahners, Bahne H
|0 0000-0003-1963-9798
|b 5
700 1 _ |a Nikolov, Petyo
|b 6
700 1 _ |a Denison, Timothy
|b 7
700 1 _ |a Saryyeva, Assel
|b 8
700 1 _ |a Krauss, Joachim K
|0 0000-0002-0675-9064
|b 9
700 1 _ |a Faust, Katharina
|b 10
700 1 _ |a Florin, Esther
|0 0000-0001-8276-2508
|b 11
700 1 _ |a Schnitzler, Alfons
|0 0000-0002-6414-7939
|b 12
700 1 _ |a Schneider, Gerd-Helge
|b 13
700 1 _ |a Kühn, Andrea A
|0 P:(DE-2719)2811089
|b 14
|e Last author
|u dzne
773 _ _ |a 10.1038/s41531-022-00301-2
|g Vol. 8, no. 1, p. 44
|0 PERI:(DE-600)2819218-7
|n 1
|p 44
|t npj Parkinson's Disease
|v 8
|y 2022
|x 2373-8057
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164058/files/DZNE-2022-00721.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164058/files/DZNE-2022-00721.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164058
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2811089
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-03
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PARKINSONS DIS : 2021
|d 2023-03-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-03-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-03-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-10-13T14:34:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-10-13T14:34:28Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-10-13T14:34:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-03-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-03-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-03-31
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PARKINSONS DIS : 2021
|d 2023-03-31
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Coordinator of Clinical Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1811005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21